Agenda-setting intelligence, analysis and advice for the global fashion community.
Danish drugmaker Novo Nordisk (NOVOb.CO) has partnered with Hims & Hers Health’s (HIMS.N) to sell its popular weight loss drug through a bundled offering on the telehealth company’s platform, the two companies said on Tuesday.
Customers will get access to the offerings of all dose strengths of Wegovy and a membership at a price starting at $599 per month, Hims said.
The offering is available this week on the Hims & Hers platform, it added.
The companies are building a longer-term roadmap of bundled offerings that will have very unique value and pricing to consumers that hopefully we’re able to share in the coming quarters, Hims CEO Andrew Dudum said.
ADVERTISEMENT
Earlier this month, Hims said it plans to sell Eli Lilly’s (LLY.N) Zepbound on its platform.
While Novo‘s Wegovy and Lilly’s rival drug, Zepbound, were in short supply, several telehealth companies were allowed to sell cheaper copies of the treatments. The branded drugs have since been removed from the US Food and Drug Administration’s shortage list, potentially curtailing bulk compounding.
The company will continue to offer personalised compounded versions of semaglutide on its platform, Dudum added.
Semaglutide is the active ingredient in Novo’s Wegovy.
By Sriparna Roy; Edited by Anil D’Silva
Learn more:
Why the Obesity Drug Revolution Is a Work in Progress
GLP-1 weight-loss drugs like Wegovy and Zepbound are revolutionising obesity treatment and generating billions for their makers, but challenges including high costs, insurance coverage issues, drug shortages, and competition from copycats could impact their widespread success.